Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;329:9 (3 July), doi:10.1136/bmj.329.7456.9-a
Debashis Singh
London
| The first 150 words of the full text of this article appear below. |
Donepezil (Aricept), a cholinesterase inhibitor approved by the National Institute for Clinical Excellence (NICE) for the treatment of Alzheimer's disease, neither slows the onset of the disease nor delays the need for patients to be taken into care, a study published in the Lancet has found (2004;363; 2105-15)[CrossRef][ISI][Medline].
The five year, double blind, randomised controlled trial conducted by the University of Birmingham and funded by the NHS concluded that routine prescribing of the drug is a waste of scarce resources.
Currently 39 000 people in the United Kingdom are taking the drug, which costs about £1000 ($1825;
1500) per person per year.
The study, called AD2000, recruited 565 patients with mild to moderate Alzheimer's disease who were living in the community. The patients were randomly assigned to either donepezil or a placebo.
It found only a marginal improvement in the mental state and
-->
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Read all Rapid Responses